Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC Patients with Ras Activated Malignancies, Long Term Results

被引：0
|
作者：
Villalona, Miguel [1 ]
Lam, Elaine [1 ]
Otterson, Gregory [1 ]
Zhao, Weqiang [2 ]
Timmons, Matthew [3 ]
Subramaniam, Deepa [4 ]
Hade, Erin [5 ]
Bertino, Erin [5 ]
Chao, Bo [1 ]
Selvaggi, Giovanni [6 ]
Knopp, Michael [7 ]
Gill, George M. [6 ]
机构：
[1] Ohio State Univ, Internal Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Pathol, Columbus, OH 43210 USA
[3] Ohio State Univ, Canc Ctr, Columbus, OH 43210 USA
[4] Georgetown Univ, Med Oncol, Washington, DC USA
[5] Ohio State Univ, Dept Med Informat, Ctr Biostat, Columbus, OH 43210 USA
[6] Oncolytics Inc, Clin Dev, Calgary, AB, Canada
[7] Ohio State Univ, Radiol, Columbus, OH 43210 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
reovirus; Kras activation; BRAF; long term survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI30.01
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
    Karapanagiotou, Eleni M.
    Roulstone, Victoria
    Twigger, Katie
    Ball, Mercel
    Tanay, MaryAnne
    Nutting, Chris
    Newbold, Kate
    Gore, Martin E.
    Larkin, James
    Syrigos, Konstantinos N.
    Coffey, Matt
    Thompson, Brad
    Mettinger, Karl
    Vile, Richard G.
    Pandha, Hardev S.
    Hall, Geoff D.
    Melcher, Alan A.
    Chester, John
    Harrington, Kevin J.
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2080 - 2089
  • [2] Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Solid Cancers
    Karapanagiotou, Eleni
    Pandha, Hardev
    Hall, Geoff
    Chester, John
    Melcher, Alan
    De Bono, Johann
    Gore, Martin
    Nutting, Christopher
    Harrington, Kevin
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 952 - 952
  • [3] Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers
    Karapanagiotou, E.
    Pandha, H. S.
    Hall, G.
    Chester, J.
    Melcher, A.
    Coffey, M.
    de Bono, J.
    Gore, M. E.
    Nutting, C. M.
    Harrington, K. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors
    Villalona-Calero, M.
    Lam, E.
    Otterson, G.
    Zhao, J.
    Timmons, M.
    Subramaniam, D.
    Hade, E.
    Gill, G. M.
    Coffey, M.
    Bertino, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 185 - 185
  • [5] THE COMBINATION CHEMOTHERAPY OF CARBOPLATIN AND WEEKLY PACLITAXEL PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED NSCLC
    Kitaguchi, S.
    Kagawa, M.
    Yamaguchi, K.
    Watanabe, M.
    Ogawa, T.
    Furonaka, O.
    Sugahara, F.
    Egawa, H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [6] FINAL RESULTS OF A PHASE 2 TRIAL OF THE ONCOLYTIC VIRUS REOVIRUS SEROTYPE 3-DEARING STRAIN (REOLYSIN®) IN METASTATIC NSCLC PATIENTS WITH A RAS-ACTIVATED PATHWAY.
    Villalona-Calero, Miguel
    Lam, Elaine
    Zhao, Weiqiang
    Otterson, Gregory
    Subramaniam, Deepa
    Chao, Bo
    Timmons, Matthew
    Schaaf, Larry
    Gill, George M.
    Coffey, Matt
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S606 - S606
  • [7] Preliminary results of the combination of paclitaxel and carboplatin for non small-cell lung cancer (NSCLC)
    Cunha, F
    Moraes, A
    Thereza, M
    Leistner, A
    Loureiro, K
    Cunha, G
    Cunha, L
    Najas, R
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 651 - 654
  • [8] Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naive Metastatic Lung Cancer (NSCLC)
    Waqar, Saiama
    Chawla, Sant
    Mathews, Brian
    Park, Dorothy
    Song, Tao
    Choi, Mi Rim
    Niederman, Thomas
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S888 - S889
  • [9] Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients (pts) with advanced NSCLC: Preliminary results of a phase II trial.
    Hanna, NH
    Estes, D
    Cress, A
    Sidor, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [10] Combination Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel for Patients with Recurrent/Metastatic NSCLC and PS of 2
    Ahmed, T.
    Triozzi, P.
    Addo, S.
    Kooski, M.
    Petty, W.
    Ruiz, J.
    Grant, S.
    D'Agostino, R.
    Bonomi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1916 - S1916
12345